An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors

Molecular Imaging and Biology

Volumn 14, Issue 3, 2012, Pages 336-347

  McCabe, Katelyn E ^a   Liu, Bin ^b   Marks, James D ^b,c   Tomlinson, James S ^a   Wu, Hong ^a   Wu, Anna M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Activated leukocyte cell adhesion molecule (ALCAM); Biomarker; Diabody; Pancreatic cancer; Positron emission tomography (PET)

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BIOLOGICAL MARKER; COPPER TETRAXETAN CYSTEINE DIABODY CU 64; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GEL ELECTROPHORESIS; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; ANIMALS; CELL LINE, TUMOR; COPPER RADIOISOTOPES; CYSTEINE; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN ENGINEERING; RATS; SINGLE-CHAIN ANTIBODIES; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; MUS;

EID: 84861481996     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-011-0500-8     Document Type: Article

References (48)

1. Wu AM (2009) Antibodies and antimatter: the resurgence of immuno- PET. J Nucl Med 50:2-5
2. Wu AM, Olafsen T (2008) Antibodies for molecular imaging of cancer. Cancer J 14:191-197
3. Wu AM, Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137-1146 (Pubitemid 41486395)
4. Cai W, Olafsen T, Zhang X et al (2007) PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med 48:304-310 (Pubitemid 47555358)
5. Olafsen T, Cheung CW, Yazaki PJ et al (2004) Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel 17:21-27 (Pubitemid 38173165)
6. Sirk SJ, Olafsen T, Barat B, Bauer KB, Wu AM (2008) Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2. Bioconjug Chem 19:2527-2534
7. King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG (2004) Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 6:R478-R487
8. Burkhardt M, Mayordomo E, Winzer KJ et al (2006) Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol 59:403-409
9. Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP (2009) Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer. Int J Cancer 125:9-14
10. Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G (2004) ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 57:1160-1164 (Pubitemid 39486521)
11. Sawhney M, Matta A, Macha MA et al (2009) Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients. Int J Cancer 124:2098-2105
12. Mezzanzanica D, Fabbi M, BagnoliMet al (2008) Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 14:1726-1733 (Pubitemid 351469457)
13. Chen R, Yi EC, Donohoe S et al (2005) Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 129:1187-1197 (Pubitemid 41446859)
14. Kristiansen G, Pilarsky C, Wissmann C et al (2003) ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 54:34-43 (Pubitemid 36043834)
15. Kristiansen G, Pilarsky C, Wissmann C et al (2005) Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 205:359-376 (Pubitemid 40253926)
16. Patel DD, Wee SF, Whichard LP et al (1995) Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells. J Exp Med 181:1563-1568
17. Bowen MA, Patel DD, Li X et al (1995) Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 181:2213-2220
18. van Kempen LC, Meier F, Egeblad M et al (2004) Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. J Invest Dermatol 122:1293-1301
19. van Kilsdonk JW, Wilting RH, Bergers M et al (2008) Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. Cancer Res 68:3671-3679
20. Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD (2004) Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res 64:704-710 (Pubitemid 38120913)
21. Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD (2007) Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. J Mol Med 85:1113-1123 (Pubitemid 47476727)
22. Roth A, Drummond DC, Conrad F et al (2007) Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther 6:2737-2746 (Pubitemid 350058154)
23. Galfre G, Milstein C (1981) Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol 73:3-46
24. Olafsen T, Gu Z, Sherman MA et al (2007) Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 30:396-405 (Pubitemid 46684429)
25. Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT (1992) High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (NY) 10:169-175
26. Olafsen T, Kenanova VE, Sundaresan G et al (2005) Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 65:5907-5916 (Pubitemid 40911197)
27. Loening AM, Gambhir SS (2003) AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2:131-137
28. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767-774
29. Leyton JV, Olafsen T, Sherman MA et al (2009) Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng Des Sel 22:209-216
30. Schmidt MM, Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8:2861-2871
31. Eder M, Knackmuss S, Le Gall F et al (2010) (68)Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. Eur J Nucl Med Mol Imaging 37:1397-1407
32. Schneider DW, Heitner T, Alicke B et al (2009) In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. J Nucl Med 50:435-443
33. Anderson CJ, Ferdani R (2009) Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm 24:379-393
34. Shokeen M, Anderson CJ (2009) Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res 42:832-841
35. Yazaki PJ, Wu AM, Tsai SW et al (2001) Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug Chem 12:220-228 (Pubitemid 32235474)
36. Ahlgren S, Wallberg H, Tran TA et al (2009) Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med 50:781-789
37. Arano Y (1998) Strategies to reduce renal radioactivity levels of antibody fragments. Q J Nucl Med 42:262-270
38. Piazza T, Cha E, Bongarzone I et al (2005) Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody. J Cell Sci 118:1515-1525 (Pubitemid 40585131)
39. 18F labeling of biomolecules for immuno-positron emission tomography. Molecular Imaging 10:168-176. doi:10.2310/7290.2010.00043
40. Horner MJ RL, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK (eds) SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, based on November 2008 SEER data submission, posted to the SEER web site, 2009. Available at http://seer.cancer.gov/csr/1975-2006/
41. Parsons CM, Sutcliffe JL, Bold RJ (2008) Preoperative evaluation of pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 15:429-435
42. Foss CA, Fox JJ, Feldmann G et al (2007) Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer. Mol Imaging 6:131-139 (Pubitemid 46955996)
43. Hausner SH, Abbey CK, Bold RJ et al (2009) Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res 69:5843-5850
44. Strickland LA, Ross J, Williams S et al (2009) Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol 218:380-390
45. Vervoort L, Burvenich I, Staelens S et al (2010) Preclinical evaluation of monoclonal antibody 14C5 for targeting pancreatic cancer. Cancer Biother Radiopharm 25:193-205
46. Mariani G, Molea N, Bacciardi D et al (1995) Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer. Cancer Res 55:5911s-5915s
47. Kahlert C, Weber H, Mogler C et al (2009) Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer 101:457-464
48. Wiiger MT, Gehrken HB, Fodstad O, Maelandsmo GM, Andersson Y (2010) A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth. Cancer Immunol Immunother 59:1665-1674